ESTRO 2025 - Abstract Book

S169

Brachytherapy -Breast

ESTRO 2025

Conclusion: No significant differences in terms of disease control or survival were identified between IORT and EBRT boosts for early-stage, high-risk breast cancer patients. In a limited-resources setting, where no SIB is available or is yet to be implemented, IORT poses an interesting alternative to shorten treatment times. Future studies should address the clinical value of IORT boost in the SIB era.

Keywords: Intraoperative radiotherapy, breast cancer, boost